Huntington’s Disease Clinical Trials Corner: August 2023
Journal of Huntington's Disease · 15.07.2023 · 12 (2) · 169-185
DOI: 10.3233/jhd-239001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Huntington's Disease, online erschienen am 15.07.2023. Verfasst von Carlos Estevez-Fraga und 2 weiteren Autor:innen. Beteiligte Einrichtung: Huntington's Disease Centre, UCL Queen Square Institute of Neurology, London, UK. Hauptthemen laut MEDLINE: Huntington Disease. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Wellcome Trust.
Abstract (Originalsprache)
In this edition of the Huntington’s Disease Clinical Trials Corner, we expand on the GENERATION HD2 (tominersen) and on the Asklepios Biopharmaceutical/BrainVectis trial with AB-1001. We also comment on the recent findings from the PROOF-HD trial, and list all currently registered and ongoing clinical trials in Huntington’s disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Huntington's Disease Centre, UCL Queen Square Institute of Neurology, London, UK.
Förderung
- Wellcome Trust
Zitieren
APA
Estevez-Fraga, C., Tabrizi, S. J., & Wild, E. J. (2023). Huntington’s Disease Clinical Trials Corner: August 2023. Journal of Huntington's Disease, 12(2), 169-185. https://doi.org/10.3233/jhd-239001
Vancouver
Estevez-Fraga C, Tabrizi SJ, Wild EJ. Huntington’s Disease Clinical Trials Corner: August 2023. Journal of Huntington's Disease. 2023;12(2):169-185. doi:10.3233/jhd-239001
BibTeX
@article{EstevezFraga2023,
author = {Estevez-Fraga, Carlos and Tabrizi, Sarah J and Wild, Edward J},
title = {Huntington’s Disease Clinical Trials Corner: August 2023},
journal = {Journal of Huntington's Disease},
year = {2023},
volume = {12},
number = {2},
pages = {169--185},
doi = {10.3233/jhd-239001}
}
EUVIMED